More ADC + IO data at #ESMO26!
Phase 2 sacituzumab tirumotecan (sac-TMT) + pembrolizumab in cisplatin-ineligible mUC (n=40) #esmo26 #oncoalert
• ORR 68%, DCR 88%
• Median DOR 19.4 mo
• Median PFS 11.2 mo
• Grade ≥3 TRAEs 63%
Activity across TROP2/PD-L1 subgroups. Promising efficacy and manageable AE profile
Response rate and PFS not are not dissimilar to early EV/P data.
12 views · 2 likes · 1 repost · 0 replies
Sacituzumab tirumotecan (Sac-TMT) + pembrolizumab (Pembro) in post-platinum advanced mismatch repair proficient (pMMR) endometrial cancer (EC)
https://esmocongress.esmo.orgComparative effectiveness of trastuzumab deruxtecan versus sacituzumab govitecan in HER2-negative metastatic breast cancer: A real-world analysis with propensity score matching
https://esmocongress.esmo.orgSacituzumab Tirumotecan (Sac-TMT) + Pembrolizumab (Pembro) for Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): Results From a Phase 2 Study (2870-002/SKB264-II-06)
https://esmocongress.esmo.orgSacituzumab Govitecan (SG) Combined With Enfortumab Vedotin (EV) and Zimberelimab (ZIM) in Treatment-Naive Metastatic Urothelial Cancer (mUC): Interim Results From Phase 1b TROPHY-U-01 Cohort 7
https://esmocongress.esmo.orgSource: David H Aggen, MD PhD · x.com